Quantifiable excess of bone resorption in monoclonal gammopathy is an early symptom of malignancy: A prospective study of 87 bone biopsies

Blood

Volumn 87, Issue 11, 1996, Pages 4762-4769

  Bataille, Régis ^a   Chappard, Daniel ^b   Basle, Michel Félix ^b  

^a INSTITUT DE BIOLOGIE   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANEMIA; ARTICLE; B CELL LEUKEMIA; B CELL LYMPHOMA; BONE BIOPSY; CANCER RISK; FOLLOW UP; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; NEUTROPENIA; OSTEOLYSIS; PRIORITY JOURNAL; RISK ASSESSMENT;

EID: 0029984076     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v87.11.4762.bloodjournal87114762     Document Type: Article

References (42)

1. Mundy GR, Bertolini DR: Bone destruction and hypercalcemia in plasma cell myeloma. Semin Oncol 13:291, 1986
2. Meszaros WT: The many facets of multiple myeloma. Semin Roentgenol 9:219, 1974
3. Durie BGM, Salmon SE: A clinical staging system for multiple myeloma. Cancer 36:842, 1975
4. Alexanian R, Barlogie B, Dixon D: Prognosis of asymptomatic multiple myeloma. Arch Intern Med 148:1963, 1988
5. Dimopoulos MA, Moulopoulos A, Smith T, Delasalle KB, Alexanian R: Risk of disease progression in asymptomatic multiple myeloma. Am J Med 94:57, 1993
6. Mundy GR, Raisz LG, Cooper RA, Schechter GP, Salmon SE: Evidence for the secretion of an osteoclast stimulating factor in myeloma. N Engl J Med 291:1041, 1974
7. Valentin-Opran A, Charhon SA, Meunier PJ, Edouard CM, Arlot ME: Quantitative histology of myeloma-induced bone changes. Br J Haematol 52:601, 1982
8. Bataille R, Chappard D, Alexandre C, Sany J: Importance of quantitative histology of bone changes in monoclonal gammopathy. Br J Cancer 53:805, 1986
9. Bataille R, Chappard D, Marcelli C, Dessauw P, Baldet P, Alexandre C, Sany J: Mechanism of bone destruction in multiple myeloma. The importance of an unbalanced process in determining the severity of lytic bone disease. J Clin Oncol 7:1909, 1989
10. Bataille R, Chappard D, Marcelli C, Rossi JF, Dessauw PH, Baldet P, Sany J, Alexandre C: Osteoblast stimulation in multiple myeloma lacking lytic bone lesions. Br J Haematol 76:484, 1990
11. Bataille R, Chappard D, Marcelli C, Dessauw P, Baldet P, Sany J, Alexandre C: Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma. J Clin Invest 88:62, 1991
12. Taube T, Beneton MNC, McCloskey EV, Rogers S, Greaves M, Kanis JA: Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption. Eur J Haematol 49:192, 1992
13. Roux C, Ravaud P, Cohen-Solal M, De Vernejoul MC, Guillemants S, Cherruau B, Delmas P, Dougados M, Amor B: Biologic, histologic and densitometric effects of oral risedronate on bone in patients with multiple myeloma. Bone 15:41, 1994
14. Bataille R, Chappard D, Basle M: Excessive bone resorption in human plasmacytomas: Direct induction by tumour cells in vivo. Br J Haematol 90:721, 1995
15. Bataille R, Chappard D, Klein B: Mechanisms of bone lesions in multiple myeloma. Hematol Oncol Clin North Am 6:285, 1992
16. Klein B, Bataille R: Cytokine network in human multiple myeloma. Hematol Oncol Clin North Am 6:273, 1992
17. Falle S, Chappard D, Vico L, Riffat G, Alexandre C: Evaluation of the osteoclastic population in iliac crest biopsies from 36 normal subjects: A histoenzymologic and histomorphometric study. J Bone Miner Res 4:501, 1989
18. Kyle RA, Greipp PHR: Smoldering multiple myeloma. N Engl J Med 302:1347, 1980
19. Kyle RA: Monoclonal gammopathy of undetermined significance. Am J Med 64:814, 1978
20. Kyle RA: "Benign" monoclonal gammopathy. After 20 to 35 years of follow-up. Mayo Clin Proc 68:26, 1993
21. Greipp PH R, Kyle RA: Clinical morphological and cell kinetic differences among multiple myeloma, monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Blood 62:166, 1993
22. 3(H)thymidine incorporation in monoclonal gammopathy of undetermined significance (MGUS), smoldering myeloma and remission phase myeloma: A reliable indicator of patients not requiring therapy. Br J Haematol 58:689, 1984
23. Roodman GD: Interleukin-6: An osteotropic factor? J Bone Miner Res 7:475, 1992
24. Kawano M, Hirano T, Matsuda T, Tagat T, Horii Y, Iwato K, Asaoku H, Tang B, Tanabe O, Tanaka H, Kuramoto A, Kishimoto T: Autocrine generation and essential requirement of BSF/2 IL-6 for human multiple myeloma. Nature 322:83, 1988
25. Klein B, Zhang XG, Jourdan M, Content J, Houssiau F, Aarden L, Piechaczyk M, Bataille R: Paracrine rather than autocrine regulation of myeloma cell growth and differentiation by interleukin-6. Blood 73:517, 1989
26. Carter A, Merchav S, Silvian-Draxler I, Tatarsky I: The role of interleukin-1 and tumor necrosis factor α in human multiple myeloma. Br J Haematol 74:424, 1990
27. Lu ZY, Bataille R, Poubelle P, Rapp MJ, Harousseau JL, Klein B: An interleukin-1 receptor antagonist (IL-IRA) blocks the IL-1 induced IL-6 paracrine production through a prostaglandin-E2 (PGE2)-related mechanism in multiple myeloma. Stem Cells 13:28, 1995 (suppl 2)
28. Lichtenstein A, Berenson J, Norman D, Chang MP, Carlile A: Production of cytokines by bone marrow cells obtained from patients with multiple myeloma. Blood 74:1266, 1989
29. Lust JA, Kline MP, Ahmann GJ, Greipp PR, Jelinek DF, Katzmann JA, Kyle RA: Correlation of IL-1 β mRNA expression with osteolytic disease and IL-6 mRNA expression with labelling index in plasma cell dyscrasias. Blood 80:468, 1992 (suppl 1)
30. Gozzolino F, Torcia M, Aldinucci DL, Rubartelli AL, Miliani A, Shaw R, Lansdorp AR, Di Guglielmo R: Production of interleukin-1 by bone marrow myeloma cells. Blood 74:380, 1989
31. Kawano M, Yamamoto I, Iwato K, Tanaka H, Asaoku H, Tanabe O, Ishikawa H, Nobuyoshi M, Ohmoto Y, Hirai Y, Kuramoto A: Interleukin-1 beta rather than lymphotoxin as the major bone resorbing activity in human multiple myeloma. Blood 73:1646, 1989
32. Hata H, Kiao H, Petrucci MT, Woodlliff J, Chang R, Epstein J: Interleukin-6 gene expression in multiple myeloma: A characteristic of immature tumor cells. Blood 81:3357, 1993
33. Borset M, Helseth E, Naume B, Waage A: Lack of IL-1 secretion from human myeloma cells highly purified by immunomagnetic separation. Br J Haematol 85:446, 1993
34. Kawano M, Tanaka H, Ishikawa H, Nobuyoshi M, Iwato K, Asaoku H, Tanabe O, Kuramoto A: Interleukin-1 accelerates autocrine growth of myeloma cells through interleukin-6 in human myeloma. Blood 73:2145, 1989
35. Matthes TH, Werner-Favre CH, Zubler RH: Cytokine expression and regulation of human plasma cells: Disappearance of interleukin-10 and persistence of transforming growth factor β1. Eur J Immunol 25:508, 1995
36. Seckinger P, Klein-Nulend J, Alander C, Thompson RC, Dayer JM, Raisz LG: Natural and recombinant human IL-1 receptor antagonists block the effects of IL-1 on bone resorption and prostaglandin production. J Immunol 145:4181, 1990
37. Delmas PD, Charrhon S, Chapuy MC, Vignon E, Briancon D, Edouard C, Meunier PJ: Long-term effects of dichloromethylene disphosphonate (CL2MDP) on skeletal lesions in multiple myeloma. Metab Bone Dis Rel Res 4:163, 1982
38. Merlini G, Parrinello GA, Piccinini L: Long-term effects of parenteral dichloromethylene bisphosphonate (CL2MBP) on bone disease of myeloma patients treated with chemotherapy. Hematol Oncol 8:23, 1990
39. Lahtinen R, Laakso M, Palva I, Virkkunem P, Elomaa I, for the Finnish Leukaemia group: Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Lancet 340:1049, 1992
40. Passeri G, Girasole G, Ulietti V, Giulani N, Pedrazzoni M, Sartori L, Jilka RL, Manolagas SC: Bisphosphonates inhibit IL-6 production by human osteoblastic cells MG63. J Bone Miner Res B2:S230, 1994 (suppl)
41. Mariette X, Khalifa P, Ravaud P, Frija J, Laval-Jeantet M, Chastang C, Brouet JC, Fermand JC: Bone densitometry in patients with multiple myeloma. Am J Med 93:595, 1992
42. Pecher Storfer M, Seibel MJ, Schuster J, Buck S, Zimmer L, Roth I, Jilch R, Kohn H, Ludwig H: Differentiation between monoclonal gammopathy of undetermined significance and multiple myeloma by urinary deoxy pyridinoline, in Proceedings of the Fifth International Myeloma Workshop. Bataille R, Harousseau JL: La Baule, France, B21:3148, 1995